LCI - Lannett launches authorized generic of Tirosint

Lannett (LCI) launched the authorized generic of Tirosint (Levothyroxine Sodium Capsules USP) and inked an exclusive U.S. distribution agreement with Switzerland-based IBSA Institut Biochimique, a global pharmaceutical company.Under the agreement, Lannett will primarily provide sales, marketing and distribution support for the product, for which it will receive a share of the profits.No other financial terms were disclosed.For the year ended Sep 2020, total U.S. sales of Levothyroxine Sodium Capsules USP were ~$111M, according to IQVIA, although actual generic market values are expected to be lower."Currently, we believe we are the sole provider of all 12 currently marketed dosage strengths for generic Levothyroxine Capsules. We expect another supplier to enter the market with a subset of dosage strengths, in due course," CEO Tim Crew commented.

For further details see:

Lannett launches authorized generic of Tirosint